MX2017004103A - Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos. - Google Patents
Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos.Info
- Publication number
- MX2017004103A MX2017004103A MX2017004103A MX2017004103A MX2017004103A MX 2017004103 A MX2017004103 A MX 2017004103A MX 2017004103 A MX2017004103 A MX 2017004103A MX 2017004103 A MX2017004103 A MX 2017004103A MX 2017004103 A MX2017004103 A MX 2017004103A
- Authority
- MX
- Mexico
- Prior art keywords
- lox1
- binding proteins
- disclosure provides
- methods
- ischemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Esta descripción proporciona proteínas de unión a LOX1 (LOX1) tales como anticuerpos contra LOX1 y composiciones y métodos para producir estas proteínas de unión. En ciertos aspectos, las proteínas de unión a LOX1 proporcionadas en la presente inhiben la actividad de LOX1 o son antagonistas respecto a ella. Además, la descripción proporciona composiciones y métodos para diagnosticar y tratar afecciones asociadas con la aterosclerosis, trombosis, arteriopatía coronaria (CAD), isquemia (por ejemplo, isquemia de miocardio), infarto (por ejemplo, infarto de miocardio), síndrome coronario agudo (ACS), accidente cerebrovascular, lesión por reperfusión, reestenosis, enfermedad vascular periférica, hipertensión, insuficiencia cardiaca, inflamación (por ejemplo, inflamación crónica), angiogénesis, preeclampsia, cáncer y otras enfermedades y afecciones mediadas por LOX1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462058254P | 2014-10-01 | 2014-10-01 | |
PCT/EP2015/072644 WO2016050889A1 (en) | 2014-10-01 | 2015-09-30 | Binding proteins specific for lox1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004103A true MX2017004103A (es) | 2017-07-07 |
Family
ID=54352455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004103A MX2017004103A (es) | 2014-10-01 | 2015-09-30 | Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos. |
Country Status (16)
Country | Link |
---|---|
US (3) | US10117889B2 (es) |
EP (1) | EP3201233A1 (es) |
JP (2) | JP6709212B2 (es) |
KR (1) | KR102571909B1 (es) |
CN (2) | CN113583130A (es) |
AU (2) | AU2015326891B2 (es) |
CA (1) | CA2962731A1 (es) |
CL (1) | CL2017000757A1 (es) |
CO (1) | CO2017003777A2 (es) |
IL (1) | IL250796B (es) |
MX (1) | MX2017004103A (es) |
MY (1) | MY188292A (es) |
NZ (1) | NZ729600A (es) |
RU (1) | RU2764993C2 (es) |
SG (2) | SG10202001114PA (es) |
WO (1) | WO2016050889A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
US9562101B2 (en) | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
MA43342A (fr) | 2015-09-30 | 2018-08-08 | Medimmune Ltd | Compositions et procédé d'inhibition de cellules souches cancéreuses |
US20230122067A1 (en) * | 2020-03-26 | 2023-04-20 | Denka Company Limited | REAGENT COMPRISING ANTIBODY FROM WHICH PART OF Fc REGION IS DELETED |
AU2021306709A1 (en) | 2020-07-06 | 2023-02-09 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting SARS-CoV-2 |
AU2021332340A1 (en) | 2020-08-26 | 2023-10-05 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
TW202306991A (zh) | 2021-04-30 | 2023-02-16 | 英商梅迪繆思有限公司 | 用於治療血管炎症、動脈粥樣硬化和相關障礙之方法 |
CN115477704B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用 |
WO2023172699A1 (en) * | 2022-03-10 | 2023-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of coronary artery disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5232818B2 (ja) * | 1998-08-06 | 2013-07-10 | 達也 沢村 | 酸化ldl受容体に対する抗体を含んでなる医薬組成物 |
US20030143226A1 (en) * | 2000-03-02 | 2003-07-31 | Yuko Kobayashi | Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof |
EP2502938B1 (en) * | 2006-10-27 | 2015-02-18 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
NZ589341A (en) * | 2007-02-23 | 2012-02-24 | Baylor Res Inst | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
US20090311271A1 (en) | 2008-05-29 | 2009-12-17 | Wyeth | Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1) |
US20120087926A1 (en) | 2009-06-18 | 2012-04-12 | Basf Coatings Gmbh | Chicken-derived anti-lox-1 antibody |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
US9562101B2 (en) * | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
-
2015
- 2015-09-30 CA CA2962731A patent/CA2962731A1/en active Pending
- 2015-09-30 US US15/516,115 patent/US10117889B2/en active Active
- 2015-09-30 JP JP2017517234A patent/JP6709212B2/ja active Active
- 2015-09-30 MX MX2017004103A patent/MX2017004103A/es unknown
- 2015-09-30 SG SG10202001114PA patent/SG10202001114PA/en unknown
- 2015-09-30 SG SG11201702385TA patent/SG11201702385TA/en unknown
- 2015-09-30 KR KR1020177011186A patent/KR102571909B1/ko active IP Right Grant
- 2015-09-30 RU RU2017115071A patent/RU2764993C2/ru active
- 2015-09-30 EP EP15784930.8A patent/EP3201233A1/en active Pending
- 2015-09-30 MY MYPI2017701123A patent/MY188292A/en unknown
- 2015-09-30 AU AU2015326891A patent/AU2015326891B2/en active Active
- 2015-09-30 WO PCT/EP2015/072644 patent/WO2016050889A1/en active Application Filing
- 2015-09-30 CN CN202110893971.3A patent/CN113583130A/zh active Pending
- 2015-09-30 CN CN201580053097.5A patent/CN108064243B/zh active Active
- 2015-09-30 NZ NZ729600A patent/NZ729600A/en unknown
-
2017
- 2017-02-26 IL IL250796A patent/IL250796B/en unknown
- 2017-03-29 CL CL2017000757A patent/CL2017000757A1/es unknown
- 2017-04-19 CO CONC2017/0003777A patent/CO2017003777A2/es unknown
-
2018
- 2018-11-02 US US16/179,135 patent/US11078284B2/en active Active
-
2020
- 2020-05-22 JP JP2020089269A patent/JP2020188765A/ja active Pending
-
2021
- 2021-07-08 AU AU2021204798A patent/AU2021204798A1/en active Pending
- 2021-07-16 US US17/377,863 patent/US20210347900A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6709212B2 (ja) | 2020-06-10 |
US10117889B2 (en) | 2018-11-06 |
CN108064243A (zh) | 2018-05-22 |
US20170304343A1 (en) | 2017-10-26 |
RU2017115071A3 (es) | 2019-04-29 |
US20190262368A1 (en) | 2019-08-29 |
SG11201702385TA (en) | 2017-04-27 |
SG10202001114PA (en) | 2020-03-30 |
AU2015326891A1 (en) | 2017-03-23 |
BR112017006609A2 (pt) | 2017-12-12 |
CL2017000757A1 (es) | 2018-04-20 |
WO2016050889A1 (en) | 2016-04-07 |
CA2962731A1 (en) | 2016-04-07 |
CN113583130A (zh) | 2021-11-02 |
KR20170062502A (ko) | 2017-06-07 |
RU2017115071A (ru) | 2018-11-07 |
JP2020188765A (ja) | 2020-11-26 |
IL250796A0 (en) | 2017-04-30 |
RU2764993C2 (ru) | 2022-01-24 |
NZ729600A (en) | 2023-09-29 |
US11078284B2 (en) | 2021-08-03 |
IL250796B (en) | 2022-04-01 |
MY188292A (en) | 2021-11-25 |
CO2017003777A2 (es) | 2017-07-11 |
JP2017531426A (ja) | 2017-10-26 |
US20210347900A1 (en) | 2021-11-11 |
EP3201233A1 (en) | 2017-08-09 |
AU2015326891B2 (en) | 2021-04-08 |
CN108064243B (zh) | 2021-08-27 |
KR102571909B1 (ko) | 2023-08-28 |
AU2021204798A1 (en) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY188292A (en) | Binding proteins specific for lox1 and uses thereof | |
WO2017087901A3 (en) | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies | |
ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
MX2021012547A (es) | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. | |
MY192226A (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
WO2016077397A3 (en) | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies | |
WO2016145426A8 (en) | Methods for diagnosis of sepsis | |
NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
MX2021006443A (es) | Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4). | |
SA518390944B1 (ar) | أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها | |
MX2017011822A (es) | Anticuerpos anti-muc16 y sus usos. | |
MD20170035A2 (ro) | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
WO2016014434A3 (en) | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
EP3463574A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LUNG VASCULAR DISEASE | |
WO2015058861A8 (en) | Bispecific constructs and their use in the treatment of various diseases | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
BR112017005713A2 (pt) | composto da fórmula (i), método de mobilização das células-tronco hematopoiéticas (hsc) e células progenitoras endoteliais (epc) na circulação periférica, método de tratamento de lesão tecidual, câncer, doença inflamatória ou doença autoimune, e composição farmacêutica | |
WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
BR112018006358A2 (pt) | métodos de conservação da atividade biológica de ácidos ribonucleicos. | |
EA201890073A1 (ru) | Получение 2,5,6-тригидрокси-3-гексеновой кислоты и 2,5-дигидрокси-3-пентеновой кислоты и их сложных эфиров из с6 и с5 сахаров | |
WO2015114633A8 (en) | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same | |
MX2015000697A (es) | Endoprótesis vascular para tratar lesiones bifurcadas en arterias coronarias. | |
EP3597185A4 (en) | BILE ACID SYNTHESIS PROMOTOR, COMPOSITION TO PROMOTE BILIC ACID SYNTHESIS, AND FOOD COMPOSITION TO PROMOTE BILIC ACID SYNTHESIS |